3.9  -0.33 (-7.8%)		10-15 16:00
Open: 4.25 High: 4.33 Volume: 2,117,116		Pre. Close: 4.23 Low: 3.9 Market Cap: 377(M)

Short term
Mid term
Targets	6-month :	5.17	1-year :	5.73
Resists	First :	4.43	Second :	4.9
Pivot price	4.3
Supports	First :	3.66	Second :	3.04
MAs	MA(5) :	4.49	MA(20) :	4.21
	MA(100) :	4.5	MA(250) :	4.6
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	42.3	D(3) :	67.2
RSI	RSI(14): 39.4
52-week	High :	11.45	Low :	1.07

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RZLT ] has closed above bottom band by 17.2%. Bollinger Bands are 22.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.34 - 4.37	4.37 - 4.39
Low:	3.83 - 3.86	3.86 - 3.89
Close:	3.85 - 3.9	3.9 - 3.94

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Wed, 14 Oct 2026
Rezolute completes enrollment in Phase 3 upLIFT; topline results expected mid-December 2026 - TradingView

Wed, 14 Oct 2026
Rezolute (RZLT) Completes Enrollment in Phase 3 Trial for Ersode - GuruFocus

Wed, 14 Oct 2026
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - Stock Titan

Fri, 09 Oct 2026
With Rezolute Up 14%, Insider Buyers Count Their Returns - Simply Wall Street

Tue, 06 Oct 2026
Rezolute (RZLT) Upgraded to Overweight by Cantor Fitzgerald on E - GuruFocus

Tue, 06 Oct 2026
Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	97 (M)
Shares Float	61 (M)
Held by Insiders	9.7 (%)
Held by Institutions	98.3 (%)
Shares Short	16,710 (K)
Shares Short P.Month	17,000 (K)

EPS	-0.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.03
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-35.4 %
Return on Equity (ttm)	-59.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.85
Qtrly Earnings Growth	0 %
Operating Cash Flow	-65 (M)
Levered Free Cash Flow	-36 (M)

PE Ratio	-5.21
PEG Ratio	0
Price to Book value	3.75
Price to Sales	0
Price to Cash Flow	-5.84

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.